Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • Clathrin-Mediated Entry of Grass Carp Reovirus

    2026-09-23

    Clathrin-Mediated Entry of Grass Carp Reovirus

    Understanding how viruses enter host cells is essential for separating attachment, internalization, endosomal trafficking, and productive replication. In the reference study, Wang and colleagues examined these steps for grass carp reovirus, with particular emphasis on genotype III strain GCRV104. The work is valuable because it combines inhibitor profiling with ultrastructural and molecular readouts rather than inferring entry from a single pharmacological marker. The full study is available in Virology Journal.

    Study Background and Research Question

    Grass carp hemorrhagic disease is associated with acute infection by grass carp reovirus, a major concern for grass carp production in Asia. GCRV belongs to the genus Aquareovirus in the family Reoviridae, and isolates have been grouped into three genotypes. GCRV-JX01 represents genotype I, whereas GCRV104 represents genotype III. The latter is especially interesting because genotype III viruses encode an outer-fiber protein, while the cellular mechanism used by this fiber-bearing virus to enter host cells was not well defined.

    The central question was whether GCRV104 uses a recognizable endocytic route in the grass carp kidney cell line CIK. More specifically, the investigators tested possible roles for clathrin, dynamin, endosomal acidification, lipid raft-associated uptake, macropinocytosis, phosphatidylinositol 3-kinase, protein kinase C, microtubules, and actin polymerization. Including GCRV-JX01 as a comparator also allowed the authors to ask whether entry requirements were shared between representative genotype I and genotype III viruses.

    Key Innovation from the Reference Study

    The main innovation was a layered entry analysis. Instead of treating viral replication as a direct proxy for internalization, the authors used a panel of inhibitors with different cellular targets and interpreted the results alongside transmission electron microscopy and real-time quantitative PCR. This design provided convergent evidence for a clathrin-mediated, pH-dependent pathway and highlighted dynamin as an important factor in productive entry.

    The study also contributes a useful negative result for actin biology. Latrunculin B did not inhibit GCRV104 or GCRV-JX01 entry and infection in the reported assays. Thus, actin filament assembly inhibition was not sufficient to block these viruses under the tested conditions. For cellular actin dynamics research, this is an important distinction: an actin polymerization inhibitor can be a mechanistic control without necessarily being an antiviral compound in every entry model.

    Methods and Experimental Design Insights

    Both viruses were propagated in CIK cells, and the investigators monitored cytopathic effect and viral growth. Pharmacological inhibitors were applied to probe specific uptake mechanisms. Ammonium chloride was used to interfere with endosomal acidification, while dynasore addressed dynamin-dependent vesicle scission. Chlorpromazine and Pitstop 2 provided pharmacological tests of clathrin-associated uptake. Other compounds examined lipid raft or cholesterol-dependent internalization, macropinocytosis, phosphatidylinositol 3-kinase, protein kinase C, microtubules, and actin polymerization.

    Transmission electron microscopy supplied morphological information about virus–cell interactions and intracellular structures. Real-time quantitative PCR supplied a molecular measure of infection or viral genome-associated signal. The combination was stronger than relying on cytopathic effect alone, because cytopathic changes may reflect later replication events rather than the initial internalization step. The authors also compared inhibitor responses between GCRV104 and GCRV-JX01, helping distinguish genotype-specific biology from a shared entry program.

    Protocol Parameters

    • Cell model: Use the CIK grass carp kidney cell system described in the reference study when reproducing the reported entry phenotype.
    • Virus comparison: Examine GCRV104 and GCRV-JX01 in parallel where possible, because the paper used genotype III and genotype I strains to assess conservation of entry requirements.
    • Inhibitor logic: Pair compounds that interrogate related mechanisms, such as dynasore, chlorpromazine, and Pitstop 2 for dynamin or clathrin-associated uptake, rather than interpreting one inhibitor in isolation.
    • Readouts: Combine cytopathic effect, transmission electron microscopy, and real-time quantitative PCR, following the experimental framework reported in the reference study.
    • Timing: Distinguish pretreatment or entry-phase effects from post-entry replication effects. The study reported a major titer difference at 24 hours after infection, so time-matched sampling is important for comparison.
    • Controls: Include vehicle, untreated infection, and cell-toxicity controls. A reduction in viral signal is not mechanistically interpretable if the inhibitor substantially damages CIK cells.

    Core Findings and Why They Matter

    Both GCRV-JX01 and GCRV104 produced a typical cytopathic effect in CIK cells, but their replication kinetics differed. GCRV104 replicated more slowly, and the reported GCRV-JX01 titer was approximately 1,000-fold higher than the GCRV104 titer at 24 hours after infection, according to the reference study. This difference is not merely descriptive: it cautions against assuming that two related reoviruses will produce equivalent inhibitor-response curves at the same sampling time.

    Ammonium chloride and dynasore significantly reduced viral entry or infection, supporting a requirement for endosomal acidification and dynamin activity. Chlorpromazine and Pitstop 2 also inhibited infection, consistent with clathrin-associated uptake. Taken together, these data support the conclusion that GCRV104 enters CIK cells through a clathrin-mediated endocytic route that depends on acidification. The similar response of GCRV-JX01 suggests that dynamin and acidic endosomal compartments may be shared features of entry for the two tested strains.

    The authors additionally reported inhibition by wortmannin and rottlerin, implicating phosphatidylinositol 3-kinase- and protein kinase C-associated processes in efficient GCRV104 entry or replication. However, not every compound associated with a candidate uptake pathway was active. Nystatin, methyl-β-cyclodextrin, IPA-3, amiloride, bafilomycin A1, nocodazole, and latrunculin B did not significantly inhibit infection in the reported experiments. The contrast between active ammonium chloride and inactive bafilomycin A1 also shows why pathway assignments should be based on convergent evidence rather than drug labels alone.

    For actin cytoskeleton disruption studies, the latrunculin B result is best interpreted narrowly. It indicates that the tested level and timing of actin polymerization perturbation did not prevent productive infection in CIK cells. It does not prove that actin has no role in attachment, membrane remodeling, intracellular trafficking, or later replication. This distinction is particularly important when applying a latrunculin b inhibitor as a control in cytoskeletal organization studies.

    Why this cross-domain matters, maturity, and limitations

    The study creates a useful bridge between aquatic virology and cellular actin dynamics research. A negative response to Latrunculin B helps researchers avoid an overly broad model in which every endocytic virus is assumed to require polymerized actin. At the same time, the evidence is pharmacological and cell-type specific. It is mature enough to support a working model of GCRV104 entry, but not sufficient to establish that actin-independent uptake is universal across fish cells, viral genotypes, or mammalian systems.

    Comparison with Existing Internal Articles

    The internal article Clathrin-Mediated Entry of Grass Carp Reovirus: Inhibitor Insights presents a closely aligned interpretation of the same study, emphasizing clathrin, dynamin, and endosomal pH. Its value is as a concise pathway-oriented companion to the primary paper; the reference study remains the stronger basis for evaluating the experimental design and inhibitor panel.

    A separate overview, Latrunculin B: Precision Actin Inhibitor for Cytoskeleton Research, focuses on actin polymerization and cellular assay applications. Read alongside Wang et al., it clarifies the distinction between a compound’s usefulness for controlled actin perturbation and its ability to suppress a particular virus. The two articles should therefore be connected conceptually, not treated as evidence that actin inhibition blocks GCRV entry.

    Limitations and Transferability

    Several limitations shape how the findings should be used. First, pharmacological inhibitors can have off-target effects, and pathway inhibitors may influence both entry and later replication. A reduction in viral output is therefore not automatically proof that a compound blocked internalization. The study’s use of multiple readouts improves confidence, but genetic depletion or rescue experiments would provide stronger causal evidence for clathrin and dynamin.

    Second, the inactive response to latrunculin B, nocodazole, or membrane-associated inhibitors is conditional. It depends on concentration, exposure time, cell state, virus dose, and the assay endpoint. Negative pharmacological results should not be converted into universal statements about the absence of actin, microtubule, or lipid-raft involvement. Follow-up work could separate binding, uptake, endosomal escape, and replication more explicitly.

    Third, CIK cells are a fish-derived culture model, and GCRV104 is a genotype III aquatic reovirus. The clathrin-mediated entry framework may guide hypotheses in other systems, but it should not be assumed to transfer directly to mammalian viruses or unrelated reoviruses. The outer-fiber architecture, receptor usage, endosomal maturation, and intracellular environment may all alter inhibitor sensitivity. Finally, the large replication difference between GCRV-JX01 and GCRV104 means that comparisons should use matched infection conditions and multiple time points rather than a single endpoint.

    Research Support Resources

    Researchers can use Latrunculin B (SKU C5804) to support similar workflows involving actin polymerization perturbation, actin cytoskeleton disruption, and cytoskeletal organization studies. The product information describes it as a cell-permeable inhibitor that binds monomeric G-actin in a 1:1 ratio; it reports ≥97% purity, solubility up to 25 mg/ml in DMSO, and storage at −20°C. Because the Wang et al. study found no inhibition of GCRV entry under its tested conditions, Latrunculin B is best used with appropriate vehicle, viability, exposure-time, and pathway controls rather than as a stand-alone antiviral reagent.